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S U M M A R Y
Background: The routine use of ﬂuoroquinolone prophylaxis in patients with neutropenia and
hematological malignancies is controversial. This prophylaxis has been reported to have a positive
impact in reducing infection-related mortality, but the consequent development of antibiotic resistance
has become a concern. This study assessed the effect of discontinuing quinolone prophylaxis on the
etiology and the resistance pattern of blood culture isolates and on the prognosis among febrile
neutropenic patients receiving chemotherapy.
Methods: The results of blood cultures obtained from febrile neutropenic patients between January 2003
and June 2009 were analyzed; these results were available through a computer database set up in 2003.
Results: Patients receiving quinolone prophylaxis between 2003 and 2005 showed a lower incidence of
Gram-negative bacteria than patients not receiving prophylaxis between 2006 and 2009 (13.5%, n = 9 vs.
48.1%, n = 75). Interestingly, after discontinuing prophylaxis, approximately 70% of the Gram-negative
bacteria isolated were quinolone-resistant, and some were extended-spectrum b-lactamase (ESBL)
producers. The frequencies of quinolone-resistant Gram-positive bacteria isolatedwere similar between
the period of quinolone prophylaxis and the period with no prophylaxis (61.1% vs. 64.3%). In both
periods, all Gram-positive isolates were sensitive to vancomycin. The infection-related mortality was
comparable between patients receiving prophylaxis and those not receiving prophylaxis (1.5%, n = 1 vs.
1.3%, n = 2).
Conclusions: These ﬁndings suggest that quinolone prophylaxis for neutropenia does not induce a
signiﬁcant increase in the growth of quinolone- and multidrug-resistant bacteria. Rather, discontinuing
quinolone prophylaxis may induce a dramatic increase in the growth of Gram-negative bacteria,
including ESBL producers. Our results suggest that the necessity for quinolone prophylaxis in
neutropenic patients should be determined based on local antibiotic resistance patterns.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Febrile neutropenia is one of the most serious adverse events in
patients with hematological malignancies and chemotherapy.1
Bacteremia related to febrile neutropenia often increases infec-
tion-related morbidity and mortality. The use of antibiotic
prophylaxis, particularly ﬂuoroquinolones (quinolones), may be
useful for preventing infectious episodes in patients with febrile
neutropenia, but its routine use remains controversial.2,3 Meta-
analyses in the 1990s failed to demonstrate a reduction in
mortality.4,5 In 2002, the Infectious Diseases Society of America
(IDSA) recommended that routine prophylaxis with quinolones
should be avoided.6 In 2005, a double-blind, placebo-controlled* Corresponding author. Tel.: +81 92 291 3434; fax: +81 92 291 3266.
E-mail address: ychong@gj9.so-net.ne.jp (Y. Chong).
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doi:10.1016/j.ijid.2010.12.010trial did not show signiﬁcant reduction inmortality in neutropenic
patients receiving quinolone prophylaxis.7 On the other hand, the
results of a meta-analysis reported in 2005 showed a statistically
signiﬁcant decrease in mortality in neutropenic patients receiving
quinolone prophylaxis;8 a dramatic increase in infection-related
mortality after discontinuing the prophylaxis was also reported in
2005.9 More recently, a meta-analysis conﬁrmed that quinolone
prophylaxis reduces mortality in neutropenic patients receiving
chemotherapy.10 Guidelines issued by the National Comprehen-
sive Cancer Network (NCCN) stated that the prophylactic use of
quinolones is recommended for ‘high-risk’ patients in whom
chemotherapy-induced neutropenia is expected to last for more
than 7 days.11
Beneﬁts of antibiotic prophylaxis in neutropenic patients
have been reported; however, the emergence of bacterial
resistance to antibiotics has become a concern, and the routine
use of prophylaxis has been repeatedly questioned. Quinolone-ses. Published by Elsevier Ltd. All rights reserved.
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detected in neutropenic patients receiving quinolone prophy-
laxis, and the developing Escherichia coli strains resistant to
quinolone have been found to be a risk factor for neutropenia-
induced bacteremia.12–14 Quinolone-resistant Gram-positive
bacteremia has also been reported in patients routinely
receiving quinolones.15 Viridans group streptococci (VGS)
resistant to quinolone were found to induce neutropenic
bacteremia in patients receiving quinolone prophylaxis.16,17
Recently, methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE) have been found
as bacteremic isolates in neutropenic patients receiving quino-
lone prophylaxis.18
In our unit, quinolone prophylaxis was routinely used in
neutropenic inpatients receiving chemotherapy until 2005;
prophylaxis was discontinued in 2006. We assessed the effect of
discontinuing quinolone prophylaxis on the etiology and the
antibiotic resistance pattern of blood culture isolates and on
mortality in neutropenic patients with hematological malignan-
cies and chemotherapy. Our study showed that quinolone
prophylaxis did not increase the growth of quinolone-resistant
bacteria. Interestingly, after the prophylaxis was discontinued,
there was a signiﬁcant increase in the detection rate of Gram-
negative bacteremic isolates, including extended-spectrum b-
lactamase (ESBL) producers. The mortality was comparable
between the two periods. Our data are useful in deciding whether




Between January 2003 and June 2009, a total of 1981 patients
were admitted to the blood and marrow transplantation unit at
Hara-Sanshin Hospital. In the present study, the results of blood
cultures obtained from febrile neutropenic patients during the
abovementioned period were analyzed; these results were
available through a computer database set up in 2003. Until
December 2005, antibiotic prophylaxis with levoﬂoxacin at a
dosage of 300 mg/day had been administered to all inpatients whoTable 1
Effect of ﬂuoroquinolone prophylaxis on the etiology of bacteremic isolates in patients
Prophylaxis given
(2003–2005)
Organism No. of isolates %
Gram-negative
Escherichia coli 6 9
Pseudomonas aeruginosa 2 3
Klebsiella pneumoniae 1 1
Other 0 0
Gram-negative, total 9 1
Gram-positive
Staphylococcus species, total 26 3
Coagulase-negative staphylococci 19 2
Staphylococcus aureus 2 3
Enterococcus species, total 18 2
Enterococcus faecium 10 1
Enterococcus faecalis 4 6
Streptococcus species, total 7 1
Viridans group streptococci 5 7
Gram-positive, total 51 7
Other 7 1
Isolates, total 67 1
a p-Value shows statistical comparison for each variable between patients receivingwere expected to have neutropenia for more than 7 days. A daily
dose of 300 mg was the maximum dosage approved for
levoﬂoxacin in Japan. The routine use of quinolone prophylaxis
for neutropenic patients was discontinued in January 2006. All
patients with neutropenia had received antimycotic agents during
both periods.
Febrile neutropenia was deﬁned as a neutrophil count of <500
cells/ml and an axillary temperature of >38.0 8C. Some agents
recommended in the IDSA guidelines had been used as initial
empirical antibiotics in patients with febrile neutropenia. Anti-
biotics were administered until recovery of neutrophil counts and/
or resolution of infections. When bacteria were isolated from a
blood culture, antimicrobial therapy was adjusted according to
their antibiotic resistance pattern. The prophylactic use of
quinolone was discontinued when empirical antibiotic therapy
was initiated.
Detailed information on patients was collected from computer
databases. These data included age, sex, malignant disease
classiﬁcations, presence of indwelling catheters, neutrophil
counts, prior antibiotic usage, and clinical outcomes. Information
on isolated strains, including etiology and susceptibility to
antibiotics, was obtained from a microbiology laboratory com-
puter database.
2.2. Microbiology
In our unit, blood culture tests are conducted for all patients
with febrile neutropenia. An automated blood culture system
(BACTEC) was used for each test. Several samples were obtained
from the same patient and treated as independent results.
Antibiotic susceptibilities were determined from the breakpoints
standardized by the Clinical and Laboratory Standards Institute
(CLSI).19 The screening and conﬁrmation tests for ESBL and
metallo-b-lactamase were conducted according to the recom-
mendations of the CLSI.19 In addition,b-lactamase producers were
conﬁrmed using a Cica b test I/MBL kit (Kanto Chemical Co. Ltd,
Tokyo, Japan). Strains that were positive for ESBL based on the
conﬁrmation tests were then evaluated for genotype. Genotyping
of metallo-b-lactamase was conducted when the screening test
was positive. PCR was conducted using ﬁve sets of primers to
amplify type-speciﬁc ESBL genes, including CTX-M, TEM, and SHVwith febrile neutropenia
No prophylaxis
(2006–2009)
No. of isolates % p-Valuea
.0 29 18.6 0.07
.0 23 14.7 <0.05
.5 14 9.0 <0.05
9 5.8 0.06
3.5 75 48.1 <0.01
8.8 52 33.3 0.4
8.4 36 23.1 0.4
.0 2 1.3 0.6
6.9 9 5.8 <0.01
4.9 6 3.8 <0.01
.0 2 1.3 0.07
0.4 10 6.4 0.4
.5 9 5.8 0.8
6.1 71 45.5 <0.01
0.4 10 6.4 0.4
00 156 100








Detection rate of ESBL
p<0.05
n.s
Figure 1. Frequencies of ESBL-producing strains in bacteremic isolates obtained
from patients with febrile neutropenia (n.s., not signiﬁcant).
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CTX-M b-lactamase genes.20 PCR was conducted using primers
speciﬁc for metallo-b-lactamase genes.
2.3. Statistical analysis
In the comparisons between patients receiving prophylaxis and
those not receiving prophylaxis, categorical variables were
analyzed using a Fisher’s exact test.
3. Results
3.1. Effects of ﬂuoroquinolone prophylaxis on the etiology of
bacteremic isolates in patients with febrile neutropenia
During the period of quinolone prophylaxis, a total of 67
bacteria were isolated from blood cultures associated with 762
episodes of febrile neutropenia (Table 1). During the period when
prophylaxis had been discontinued, a total of 156 bacteria were
recovered fromblood culture isolates associatedwith 931 episodes
of febrile neutropenia (Table 1). After prophylaxis was discon-
tinued, the incidence of Gram-negative isolates, including E. coli,
Pseudomonas aeruginosa, and Klebsiella pneumoniae, signiﬁcantly
increased. Gram-positive organismswere detectedmore frequent-
ly in the prophylaxis period than in the periodwith no prophylaxis.
The incidence of Staphylococcus species was similar in both
periods, and MRSA was not isolated in either of the two periods.
The detection rate of Enterococcus species dramatically decreased
after the prophylaxis was discontinued. Enterococcus species
accounted for 30% of all isolates analyzed during the prophylaxis
period, and both Enterococcus faecium and Enterococcus faecalis
were sensitive to vancomycin. The incidence of VGS was similar in
both periods.
3.2. Antimicrobial susceptibilities of Gram-negative isolates from
patients with febrile neutropenia and bacteremia
Gram-negative isolates were characterized with respect to the
production of b-lactamase enzymes. Screening of strains produc-
ing ESBL andmetallo-b-lactamasewas conducted. No P. aeruginosa
isolates that were metallo-b-lactamase producers were detected
in either of the two periods. There were no ESBL producers in theTable 2
Susceptibility of Escherichia coli isolated from febrile neutropenic patients with bactere
Prophylaxis given (2003–2005)
Antibiotic MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%)
Levoﬂoxacin 1 1 0.0
Ciproﬂoxacin 0.5 0.5 0.0
MIC, minimum inhibitory concentration.
a p-Value shows statistical comparison for each variable between patients receiving
Table 3
Susceptibility of Gram-positive isolates to levoﬂoxacin in febrile neutropenic patients
Prophylaxis given (2003–2005)
MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%
Organism
Gram-positive, total 4 8 61.1
Staphylococcus species 4 8 60.0
Enterococcus species 8 8 80.0
Streptococcus species 2 8 33.3
MIC, minimum inhibitory concentration.
a p-Value shows statistical comparison for each variable between patients receivingprophylaxis period. On the other hand, in the period after
prophylaxis was discontinued, 14 of 29 E. coli isolates (48.3%)
and 2 of 14 K. pneumoniae isolates (14.3%) were found to be ESBL-
producing strains (Figure 1), and all were conﬁrmed to be isolates
containing ESBL genes at the molecular level. Approximately 90%
of the ESBL-producing strains contained the genes encoding CTX-
M-types, of which the CTX-M-9 group accounted for the majority.
The rates of detection of E. coli isolates resistant to quinolones
were then compared between the two periods (Table 2). There
were no quinolone-resistant E. coli isolates during the period with
prophylaxis, whereas 70% of the isolates were resistant to
quinolones after prophylaxis was discontinued. ESBL-producing E.
coli isolates detected in the period with no prophylaxis were all
resistant to quinolones and comprised 70% of the E. coli isolates
resistant to quinolones.
3.3. Antimicrobial susceptibilities of Gram-positive isolates from
patients with febrile neutropenia and bacteremia
The incidence of quinolone-resistant Gram-positive isolates was
compared between the two periods (Table 3). Approximately 60% of
Gram-positive strains isolated during the prophylaxis period were
resistant to quinolone, and the rate of detection of resistant isolatesmia
No prophylaxis (2006–2009)
MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%) p-Value
a
8 8 64.0 <0.01
4 4 68.0 <0.01
prophylaxis and those not receiving prophylaxis.
with bacteremia
No prophylaxis (2006–2009)
) MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%) p-Value
a
4 8 64.3 0.9
4 8 69.4 0.6
8 8 88.9 0.9
1 8 25.0 0.6
prophylaxis and those not receiving prophylaxis.
Table 4
Susceptibility of Gram-positive isolates to vancomycin in febrile neutropenic patients with bacteremia
Prophylaxis given (2003–2005) No prophylaxis (2006–2009)
Organism MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%) MIC50 (mg/ml) MIC90 (mg/ml) Resistance rate (%)
Gram-positive, total 0.5 2 0.0 1 2 0.0
Staphylococcus species 2 2 0.0 2 2 0.0
Enterococcus species 0.5 0.5 0.0 1 1 0.0
Streptococcus species 0.5 0.5 0.0 0.5 1 0.0
MIC, minimum inhibitory concentration.
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quinolone-resistant VGS isolates was 30% during each period and
comparable between the two periods.
Susceptibility to vancomycin was then compared in Gram-
positive strains isolated during the two periods (Table 4). The
majority of the Gram-positive isolates from both periods were
favorably sensitive to vancomycin. No VRE were detected in either
of the two periods.
Serial bloodcultureswereacquired for 54of67 isolates (80.6%) in
the period of quinolone prophylaxis and 129 of 156 isolates (82.7%)
in the period with no prophylaxis. In both periods, the detected
bacteriawereeliminatedafterantibiotic treatment.Onepatientdied
during treatment in the prophylaxis period and two died during the
period with no prophylaxis. All cases were possibly attributable to
septic shock caused by P. aeruginosa. Thus, the mortality related to
bacteremia was similar between patients who did and did not
receive quinolone prophylaxis (1.5%, n = 1 vs. 1.3%, n = 2).
4. Discussion
Some data on the etiology of blood culture isolates in patients
with febrile neutropenia have been reported. The incidence of
Gram-negative bacteria was reported to be signiﬁcantly higher in
patients not receiving quinolone prophylaxis than in those
receiving quinolone prophylaxis.21 In addition, there are some
reports in which the detection rate of Gram-negative isolates
dramatically increased in episodes of febrile neutropenia after
prophylaxis was discontinued.9,12 The data of the present study are
consistent with these reports. Patients not receiving quinolone
prophylaxis were found to have a similar detection rate of P.
aeruginosa isolates as compared to those receiving prophylaxis.21
In our study, the incidence of P. aeruginosa isolates increased after
quinolone prophylaxis was discontinued. This suggests that the
detection rates of Gram-negative bacteria, including P. aeruginosa,
increase without prophylaxis. Patients receiving quinolone pro-
phylaxis were reported to have a higher incidence of Gram-
positive isolates than those not receiving the prophylaxis, and the
chief strain was coagulase-negative staphylococci (CoNS) and not
Enterococcus species.21 In our study, the incidence of Enterococcus
species, in addition to CoNS, was high (30%) in the prophylaxis
period and considerably lower after prophylaxis was discontinued.
One study showed that the isolation of Enterococcus species
signiﬁcantly increased after initiating quinolone prophylaxis.18
Enterococcus species may be prevalent in blood culture isolates
from febrile neutropenic patients receiving quinolone prophylaxis.
The detection of quinolone-resistant Gram-negative bacteria in
blood cultures of patients receiving prophylaxis has been
reported.12–14 In the present study, patients not receiving
prophylaxis had a higher incidence of quinolone-resistant Gram-
negative isolates than those receiving prophylaxis. The number of
isolated Gram-negative bacteria was small in the prophylaxis
period (Table 1); nonetheless, it can be concluded that the
resistance of Gram-negative bacteria to quinolones is not induced
by quinolones alone. In this study, ESBL producers were found in
large numbers after quinolone prophylaxis was discontinued, andESBL producers accounted for 70% of Gram-negative bacteria
resistant to quinolones. ESBL-producing bacteria are reported to be
resistant to quinolones; this indicates a direct association between
ESBL genes and quinolone resistance genes.22 At our institution,
CTX-M-types were predominant in the genotyping of ESBLs. CTX-
M-producing bacteria not only cause nosocomial infections, but
also acquire the potential to spread throughout community
environments, and are currently emerging worldwide.23 It is
therefore questioned whether quinolone prophylaxis can protect
against the spread of ESBL-producing bacteria. It is interesting that
the spread of ESBLs was detected after quinolone prophylaxis was
discontinued.
Bacteremia due to Gram-positive strains resistant to quinolones
has been reported in patients receiving quinolone prophylaxis.15,18
In addition, quinolone-resistant VGS isolates have frequently been
detected in such patients.16,17 In the present study, the detection
rates of quinolone-resistant Gram-positive isolates did not change
even after the prophylaxis was discontinued. The majority of
Streptococcus species were VGS, and the incidence of VGS isolates
was also similar between patients receiving quinolones and those
not receiving quinolones. These ﬁndings suggest that quinolone
prophylaxis does not increase the growth of quinolone-resistant
Gram-positive bacteria.
A local antibiotic resistance pattern may be associated with the
persistence of quinolone resistance even after the discontinuation
of prophylaxis. In our unit, vancomycin is added when Gram-
positive bacteremia is detected in patients with febrile neutrope-
nia, as recommended by IDSA guidelines.6 Therefore, resistance to
vancomycin becomes ofmajor concern in such cases. In the present
study, quinolone prophylaxis did not increase resistance to
vancomycin. Enterococcus species were detected more frequently
in the period of quinolone prophylaxis than in the period of no
prophylaxis (Table 1), and were sensitive to vancomycin in both
periods. An increase in the isolation of VRE strains after starting
quinolone prophylaxis has been reported.18 The emergence of VRE
may be related not to the use of quinolones, but to the local and
epidemic spread of the bacteria.
In this study, quinolone prophylaxis did not affect infection-
related mortality in patients with febrile neutropenia. During the
period of quinolone prophylaxis, Gram-positive bacteria were the
chief strains in blood culture isolates and were all susceptible to
vancomycin. After prophylaxis was discontinued, Gram-negative
bacteria were frequently isolated. Interestingly, ESBL-producing
bacteria were also detected chieﬂy from E. coli isolates andwere all
eliminated by the use of carbapenems. In this study, all patient
deaths were related to septic shock caused by P. aeruginosa,
irrespective of quinolone prophylaxis. Considering that discontin-
uation of prophylaxis increased the incidence of P. aeruginosa
isolates, the mortality may gradually increase in patients not
receiving quinolone prophylaxis over a longer observation period.
This opinion is supported by ameta-analysis that reported a higher
death rate in the case of no prophylaxis.10 Therefore, the
prophylactic use of quinolones is recommended, particularly for
high-risk patients, such as those with acute leukemia, in whom
chemotherapy-induced neutropenia is expected to persist formore
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recommended in patients receiving chemotherapy for solid tumors
or lymphoma at least during the ﬁrst cycle of chemotherapy.10 In
our unit, when quinolone prophylaxis is resumed in neutropenic
patients, careful surveillance will be needed, particularly for the
susceptibility of Gram-positive isolates to vancomycin.
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